Fig. 4From: B-cell imaging with zirconium-89 labelled rituximab PET-CT at baseline is associated with therapeutic response 24 weeks after initiation of rituximab treatment in rheumatoid arthritis patientsMaximum intensity projection whole-body 89Zr-rituximab positron emission tomography image, demonstrating the biodistribution in a patient with rheumatoid arthritisBack to article page